Pharma channel feed

Bill Haney's Sky­hawk spears an­oth­er mar­quee al­liance for its work drug­ging RNA in Take­da neu­ro pact

7 years ago
People
R&D

Pfiz­er en­ters Al­ny­lam, Ion­is' TTR turf with ear­ly ap­proval for car­diomy­opa­thy drug, car­ry­ing a $225K price tag

7 years ago
R&D

Hit by set­backs, Lund­beck­'s Deb­o­rah Dun­sire inks a $400M cannabi­noid buy­out, adding a dis­cov­ery site

7 years ago
People
Deals

The (cor­rect­ed) list of the world's top 20 phar­ma com­pa­nies

7 years ago

FDA re­jects Aca­ci­a's lead drug — again — due to the same man­u­fac­tur­ing is­sue

7 years ago

As back­lash mounts in the wake of a dis­as­trous PhI­II flop, Ei­sai goes deep­er with 2 new hires

7 years ago
People
R&D

Did a dis­as­ter crush your stock in 2018? These biotechs were hap­py to come up with some rich com­pen­sa­tion deals for the CEO any­way

7 years ago
People

In­sys founder, for­mer ex­ecs face decades in jail af­ter be­ing found guilty in land­mark opi­oid case

7 years ago
People

Wood­cock de­tails up­com­ing changes to NDA and BLA re­view process

7 years ago

Sanofi's con­tro­ver­sial dengue vac­cine wins FDA ap­proval, with a raft of caveats

7 years ago

Man­u­fac­tur­ing is­sues hob­ble Heron's quest to mar­ket its long-act­ing non-opi­oid painkiller

7 years ago

FDA adds boxed warn­ings to in­som­nia med­i­cines fol­low­ing in­juries, deaths

7 years ago

As Mer­ck cel­e­brates ris­ing flow of Keytru­da cash, ex­ecs plot fa­cil­i­ty shut­downs, lay­offs in $1.2B re­or­ga­ni­za­tion

7 years ago

As Pralu­ent Q1 sales miss Wall Street ex­pec­ta­tions, FDA ex­pands drug's la­bel to re­flect CV risk re­duc­tion

7 years ago

Keytru­da PhI­II fail­ure in gas­tric can­cer blights Mer­ck­'s quest for front­line dom­i­nance

7 years ago
R&D

‘Some­thing needs to change’: An Al­ler­gan an­a­lyst spells out why next week’s vote could still spark a ma­jor re­vamp

7 years ago
People

DoJ ex­pands crack­down on Medicare kick­back schemes — Astel­las and Am­gen to pay near­ly $125M to re­solve al­le­ga­tions

7 years ago

Top 20 play­ers: Every­body loves an or­phan — es­pe­cial­ly when they come with block­buster sales and a long run of ex­clu­siv­i­ty

7 years ago
Cell/Gene Tx

As it takes Lartru­vo off the shelves, Lil­ly is set­ting up pro­gram to pro­vide drug ac­cess to cur­rent pa­tients

7 years ago

US sen­a­tors, ac­tivists chas­tise Gilead­'s Tru­va­da pric­ing, spot­light­ing CDC patents on drug's use as HIV pre­ven­tion pill

7 years ago

Whale watch­ing: What a decade of change at Big Phar­ma taught us about cor­po­rate phe­no­types

7 years ago
Deals
Biotech Voices

In­censed by Chi­na CRISPR scan­dal, US con­sor­tium am­pli­fy glob­al call to sus­pend hu­man em­bryo edit­ing

7 years ago
R&D

Drug dis­trib­u­tor, for­mer ex­ecs charged for fu­el­ing opi­oid cri­sis as le­gal cam­paign widens its scope

7 years ago

Anx­ious to fill Hu­mi­ra-sized rev­enue hole ahead of US patent cliff, Ab­b­Vie hits the ground run­ning with FDA ap­proval for Skyrizi

7 years ago
R&D
First page Previous page 270271272273274275276 Next page Last page
A service from the Financial Times